MX2015005948A - Polipeptidos para transporte de barrera hematoencefalica. - Google Patents

Polipeptidos para transporte de barrera hematoencefalica.

Info

Publication number
MX2015005948A
MX2015005948A MX2015005948A MX2015005948A MX2015005948A MX 2015005948 A MX2015005948 A MX 2015005948A MX 2015005948 A MX2015005948 A MX 2015005948A MX 2015005948 A MX2015005948 A MX 2015005948A MX 2015005948 A MX2015005948 A MX 2015005948A
Authority
MX
Mexico
Prior art keywords
polypeptides
brain barrier
blood brain
bbb
barrier transport
Prior art date
Application number
MX2015005948A
Other languages
English (en)
Inventor
Salvador Borros Gomez
Francesc Xavier Rivero Monso
Anna Cascante Cirera
Original Assignee
Sagetis Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagetis Biotech Sl filed Critical Sagetis Biotech Sl
Publication of MX2015005948A publication Critical patent/MX2015005948A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención provee polipéptidos que cruzan la barrera hematoencefálica (BBB, por sus siglas en inglés). Estos polipéptidos son, por lo tanto, agentes de transporte de BBB. Los polipéptidos son típicamente capaces de cruzar la BBB en un nivel que resulta efectivo y útil desde el punto de vista terapéutico o del diagnóstico o bien, fisiológicamente significativo, ya sea solos o cuando se encuentran acoplados a un agente terapéutico o de diagnóstico.
MX2015005948A 2012-11-14 2013-11-14 Polipeptidos para transporte de barrera hematoencefalica. MX2015005948A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1220474.9A GB201220474D0 (en) 2012-11-14 2012-11-14 Polypeptides
PCT/IB2013/060137 WO2014076655A1 (en) 2012-11-14 2013-11-14 Polypeptides for blood brain barrier transport

Publications (1)

Publication Number Publication Date
MX2015005948A true MX2015005948A (es) 2015-12-01

Family

ID=47470579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005948A MX2015005948A (es) 2012-11-14 2013-11-14 Polipeptidos para transporte de barrera hematoencefalica.

Country Status (14)

Country Link
US (1) US20150376237A1 (es)
EP (1) EP2919798A1 (es)
JP (1) JP2016539076A (es)
KR (1) KR20150100655A (es)
CN (1) CN104968359A (es)
AR (1) AR093479A1 (es)
AU (1) AU2013346420A1 (es)
CA (1) CA2890704A1 (es)
GB (1) GB201220474D0 (es)
HK (1) HK1213789A1 (es)
MX (1) MX2015005948A (es)
RU (1) RU2015122666A (es)
TW (1) TW201427994A (es)
WO (1) WO2014076655A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1907009A4 (en) 2005-07-15 2009-09-02 Angiochem Inc USE OF APROTININ POLYPEPTIDES AS CARRIER IN PHARMACEUTICAL CONJUGATES
CN102245642A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 Glp-1激动剂的结合物及其用途
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF
US10251935B2 (en) * 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
AU2015265487B2 (en) 2014-05-28 2020-08-13 Nono Inc. Chloride salt of TAT-NR2B9c
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
EP3465212A4 (en) 2016-05-23 2020-01-08 California Institute of Technology REGULAR FLORAL REGULATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
US10702589B2 (en) 2016-10-04 2020-07-07 Ann And Robert H. Lurie Children's Hospital Of Chicago Compositions and methods of treating neurological disorder and stress-induced conditions
EP3624782A4 (en) 2017-05-15 2021-05-05 Axial Biotherapeutics, Inc. INHIBITORS OF MICROBIALLY INDUCED AMYLOID
CN109422801B (zh) * 2017-08-31 2022-07-08 复旦大学 多功能靶向多肽rap及其在制备肿瘤靶向递送系统中的用途
EP3806887A4 (en) * 2018-06-13 2022-04-06 California Institute of Technology NANOPARTICLES FOR CROSSING THE BLOOD-BRAIN BARRIER AND METHODS OF TREATMENT USING IT
KR102320650B1 (ko) * 2019-10-16 2021-11-04 주식회사 시선테라퓨틱스 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체 및 이를 포함하는 조성물
JP2023506703A (ja) 2019-12-04 2023-02-20 ダンタリ インコーポレイテッド 治療用ナノ粒子を合成するための方法及び組成物
EP4142737A4 (en) * 2020-04-27 2024-06-05 Aruna Bio Inc BINDING AGENTS AND USES THEREOF FOR CENTRAL NERVOUS SYSTEM DEPRESSION
WO2023128122A1 (ko) * 2021-12-29 2023-07-06 주식회사 펩스젠 혈액뇌장벽 투과능을 가지는 펩타이드 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
DE69625575T2 (de) * 1995-10-25 2003-09-25 Senju Pharma Co Angiogense-Inhibitor
JP3996659B2 (ja) * 1995-10-25 2007-10-24 千寿製薬株式会社 血管新生抑制剤
EP0928786B1 (en) * 1995-10-25 2003-01-02 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
US7361821B2 (en) * 2002-09-20 2008-04-22 Intel Corporation Controlled alignment of nanobarcodes encoding specific information for scanning probe microscopy (SPM) reading
WO2008036682A2 (en) * 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2132224B1 (en) * 2007-03-21 2011-12-28 Raptor Pharmaceutical Inc Cyclic receptor-associated protein (rap) peptides
WO2009075836A2 (en) * 2007-12-10 2009-06-18 The Brigham And Women's Hospital, Inc. Rap variants for drug delivery
WO2010088729A1 (en) * 2009-02-04 2010-08-12 University Of Tasmania Through The Menzies Research Institute Compositions and uses therefor
WO2011119608A1 (en) * 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
JP2014518862A (ja) * 2011-05-09 2014-08-07 インスティトゥト・キミク・デ・サリア 薬物送達用ポリマーナノ粒子

Also Published As

Publication number Publication date
WO2014076655A1 (en) 2014-05-22
KR20150100655A (ko) 2015-09-02
RU2015122666A (ru) 2017-01-10
AU2013346420A1 (en) 2015-05-28
CN104968359A (zh) 2015-10-07
EP2919798A1 (en) 2015-09-23
JP2016539076A (ja) 2016-12-15
US20150376237A1 (en) 2015-12-31
AR093479A1 (es) 2015-06-10
TW201427994A (zh) 2014-07-16
HK1213789A1 (zh) 2016-07-15
GB201220474D0 (en) 2012-12-26
CA2890704A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
MX2015005948A (es) Polipeptidos para transporte de barrera hematoencefalica.
IL265774B (en) Diagnosis, prevention and treatment of joint diseases
NZ711373A (en) Fragments of p97 and uses thereof
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
PH12014501702A1 (en) Imidazopyrrolidinone compounds
IN2014DN09782A (es)
PH12014501844A1 (en) Peptidomimetic macrocycles
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
EP3068442A4 (en) Bionanofluid for use as a contrast, imaging, disinfecting and/or therapeutic agent
BR112013018996A2 (pt) conjunto monitor de ecg utilizado junto ao corpo
IN2014CN02616A (es)
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX370264B (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
WO2012156296A8 (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
HK1214526A1 (zh) 眼底疾病治療劑
EP2861177A4 (en) MEDICAL MANIPULATOR, MEDICAL SYSTEM COMPRISING SAME, MEDICAL PUNCTURE SYSTEM AND BIOPSY SYSTEM
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
GB2518801B (en) Improvements in, or relating to, caskets or coffins
HK1207579A1 (en) Composition for preventing or treating heart disease
WO2015069883A8 (en) Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same
MX2015012043A (es) Agonistas muscarinicos.
LV14848A (lv) Farmaceitiska kompozīcija trimetilamīna N-oksīda līmeņa pazemināšanai
MX2013011096A (es) Metodos de tratamiento dirigido a degeneracion lobular frontotemporal.
PL2745768T3 (pl) Medyczny indykator stopy cukrzycowej